[ad_1]
The advent of vaccines promises a return to a more normal life and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies.
Among the biggest winners are Moderna and Pfizer, two different US pharmaceutical companies that receive more than $ 30 per person for protection with their two-dose vaccine. While Moderna was created only 11 years ago, it had never made a profit and before the pandemic had only 830 employees, Pfizer has its roots in 1849 and had a net profit of $ 9.6 billion last year, with nearly 80 thousand staff members.
But other drugmakers, such as British-Swedish AstraZeneca and American Johnson & Johnson, have promised to offer their vaccines on a non-profit basis until the pandemic is over. Whether the market will remain a money-maker in the future depends on whether the vaccine will be of the type that will be needed only once, such as measles, or whether it will be required regularly, e.g. flu. But in the immediate future, there will be satisfactory profits. Meanwhile, the British “The Guardian” has drafted a classification of its own, which of these pharmaceutical companies will earn the most and which shareholders have made assets so far.
The first ranks Pfizer and BioNTech where world governments have ordered about 780 million doses, with a price of $ 39 for two doses in the US and $ 30 in the EU. In 2021, that of $ 15-30 billion from sales. Pfizer and BioNTech share profits on equal margins while BioNTech founders Ugur Sahin and Ozlem Tureci, both doctors, became multibillionaires last year when vaccine potential and the deal with Pfizer boosted the company’s stock. The Guardian then lists Moderna, Johnson & Johnson, AstraZeneca, Sinovac, the Gamaleya institute and the Russian investment fund, Novavax and CureVac.
top channel
[ad_2]
Source link
